阿库提斯生物制药 ARQT
$25.55 −$1.45 (-5.37%)
休市 · Nov 8, 5:10 am ET · 最新盘后价 $25.55 0.00%
开盘$26.70
昨收$27.00
当日区间$25.29 – $27.09
成交量3.26M
市值$3.23B
市盈率（TTM）116.1
股息率–
ARQT 相关新闻
匹配 Arcutis Biotherapeutics 或代码 ARQT 的头条新闻，按最新排序。
- Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common Stocks
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40
- H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34
- Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
- Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
- Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
- Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
- H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
- Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35 负面
- A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37
暂无评论——快来第一个聊聊 ARQT。
登录后参与讨论。